Compare Starbucks Corp (SBUX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Twist Bioscience Corp — how do they compare? Starbucks Corp trades at $100.25 (market cap $116.29B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Starbucks Corp is far larger — about 13.8× Twist Bioscience Corp's market cap, and Starbucks Corp pays a 2.43% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SBUX | TWST | |
|---|---|---|
Market Cap | $116.29B | $8.42B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $153.10 |
52-Week Low | $78.46 | $24.16 |
Enterprise Value | $135.12B | $8.35B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $37.18B in 2025, though net income margin compressed to 5.17%. The stock faces headwinds from high valuation multiples (P/E 58.97) and negative shareholder equity, but analyst consensus remains positive with a $113.60 price target. Recent news highlights CEO Niccol's turnaround progress and record sales from seasonal offerings.
Outlook is mixed: operational improvements and debt reduction support upside, but margin pressure and union disputes pose risks. The stock offers growth potential if execution continues, yet investors must weigh high valuation against competitive and labor challenges in the coffee retail sector.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
